Antibody deficiency secondary to chronic lymphocytic leukemia: Should patients be treated with prophylactic replacement immunoglobulin?

Journal of Clinical Immunology

Volumn 34, Issue 3, 2014, Pages 277-282

  Dhalla, Fatima ^a,b   Lucas, M Mary ^a,b   Schuh, A Anna ^c   Bhole, M Malini ^d   Jain, R Rashmi ^a,b   Patel, Smita Y ^a,b   Misbah, Siraj ^a,b   Chapel, Helen ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c CHURCHILL HOSPITAL   (United Kingdom)

^d RUSSELLS HALL HOSPITAL   (United Kingdom)

Author keywords

CLLhypogammaglobulinemiareplacement immunoglobulin

Indexed keywords

ANTIBIOTIC AGENT; IMMUNOGLOBULIN; PLACEBO; PNEUMOCOCCUS POLYSACCHARIDE; RITUXIMAB;

ANTIBIOTIC PROPHYLAXIS; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; BACTERIAL INFECTION; BRONCHIECTASIS; CHRONIC LYMPHATIC LEUKEMIA; COST EFFECTIVENESS ANALYSIS; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; LUNG FUNCTION TEST; MULTIPLE MYELOMA; NEUTROPENIA; NEUTROPHIL COUNT; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); AGAMMAGLOBULINEMIA; COMPLICATION; IMMUNOLOGY; OPPORTUNISTIC INFECTIONS;

AGAMMAGLOBULINEMIA; ANTIBIOTIC PROPHYLAXIS; HUMANS; IMMUNOGLOBULINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; OPPORTUNISTIC INFECTIONS;

EID: 84898057363     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-014-9995-5     Document Type: Article

References (30)

1. Hamblin AD, Hamblin TJ. The immunodeficiency of chronic lymphocytic leukaemia. Br Med Bull. 2008;87:49-62.
2. Morrison VA. Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches. Best Pract Res Clin Haematol. 2010;23(1):145-53.
3. Itälä M, Helenius H, Nikoskelainen J, Remes K. Infections and serum IgG levels in patients with chronic lymphocytic leukemia. Eur J Haematol. 1992;48(5):266-70.
4. Colovic N, Bogdanovic A, Martinovic-Cemerikic V, Jankovic G. Prognostic significance of serum immunoglobulins in B- chronic lymphocytic leukaemia. Arch Oncol. 2001;9(2):4.
5. Griffiths H, Lea J, Bunch C, Lee M, Chapel H. Predictors of infection in chronic lymphocytic leukaemia (CLL). Clin Exp Immunol. 1992;89(3):374-7.
6. Kay NE. Abnormal T-cell subpopulation function in CLL: excessive suppressor (T gamma) and deficient helper (T mu) activity with respect to B-cell proliferation. Blood. 1981;57(3):418-20.
7. Hersey P, Wotherspoon J, Reid G, Gunz FW. Hypogammaglobulinaemia associated with abnormalities of both B and T lymphocytes in patients with chronic lymphatic leukaemia. Clin Exp Immunol. 1980;39(3):698-707.
8. Sampalo A, Navas G, Medina F, Segundo C, Cámara C, Brieva JA. Chronic lymphocytic leukemia B cells inhibit spontaneous Ig production by autologous bone marrow cells: role of CD95-CD95L interaction. Blood. 2000;96(9):3168-74.
9. Weeks JC, Tierney MR, Weinstein MC. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med. 1991;325(2):81-6.
10. Oscier D, Dearden C, Eren E, Erem E, Fegan C, Follows G, et al. Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. Br J Haematol. 2012;159(5):541-64.
11. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446-56.
12. Mellemgaard A, Brown P, Heron I, Geisler C, Hansen M, Moesgaard F, et al. Ranitidine improves the vaccination response in patients with chronic lymphocytic leukaemia - a randomised, controlled study. Immunol Infect Dis. 1993;3:3.
13. Sinisalo M, Aittoniemi J, Oivanen P, Käyhty H, Olander RM, Vilpo J. Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia. Br J Haematol. 2001;114(1):107-10.
14. Hartkamp A, Mulder AH, Rijkers GT, van Velzen-Blad H, Biesma DH. Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia. Vaccine. 2001;19(13-14):1671-7.
15. Sinisalo M, Vilpo J, Itälä M, Väkeväinen M, Taurio J, Aittoniemi J. Antibody response to 7-valent conjugated pneumococcal vaccine in patients with chronic lymphocytic leukaemia. Vaccine. 2007;26(1):82-7.
16. Chapel HM, Lee M, Hargreaves R, Pamphilon DH, Prentice AG. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet. 1994;343(8905):1059-63.
17. Beck SC. Making sense of serotype-specific pneumococcal antibody measurements. Ann Clin Biochem. 2013;50(Pt 6):517-9.
18. Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):660-7.
19. Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol. 2010;125(6):1354-60.e4.
20. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. N Engl J Med. 1988;319(14):902-7.
21. Griffiths H, Brennan V, Lea J, Bunch C, Lee M, Chapel H. Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors. Blood. 1989;73(2):366-8.
22. Boughton BJ, Jackson N, Lim S, Smith N. Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia. Clin Lab Haematol. 1995;17(1):75-80.
23. Jurlander J, Geisler CH, Hansen MM. Treatment of hypogammaglobulinaemia in chronic lymphocytic leukaemia by low-dose intravenous gammaglobulin. Eur J Haematol. 1994;53(2):114-8.
24. Chapel H, Dicato M, Gamm H, Brennan V, Ries F, Bunch C, et al. Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimes. Br J Haematol. 1994;88(1):209-12.
25. Molica S, Musto P, Chiurazzi F, Specchia G, Brugiatelli M, Cicoira L, et al. Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study. Haematologica. 1996;81(2):121-6.
26. Sklenar I, Schiffman G, Jønsson V, Verhoef G, Birgens H, Boogaerts M, et al. Effect of various doses of intravenous polyclonal IgG on in vivo levels of 12 pneumococcal antibodies in patients with chronic lymphocytic leukaemia and multiple myeloma. Oncology. 1993;50(6):466-77.
27. Bauer K, Rancea M, Roloff V, Elter T, Hallek M, Engert A, et al. Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia. Cochrane Database Syst Rev. 2012;11, CD008079.
28. Ducruet T, Levasseur MC, Des Roches A, Kafal A, Dicaire R, Haddad E. Pharmacoeconomic advantages of subcutaneous versus intravenous immunoglobulin treatment in a Canadian pediatric center. J Allergy Clin Immunol. 2013;131(2):585-7.e1-3.
29. Nicolay U, Kiessling P, Berger M, Gupta S, Yel L, Roifman CM, et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol. 2006;26(1):65-72.
30. Alexandrescu DT, Wiernik PH. Serum globulins as marker of immune restoration after treatment with high-dose rituximab for chronic lymphocytic leukemia. Med Oncol. 2008;25(3):309-14.